ImetelChat

Moderna has a large oncology division, working on mRNA vaccines that can be customized against any cell with a mutated antigen.

It is almost back to where it was in 2018 before the Discontinuation.

High short interest is a good statistical predictor of stock underperformance.

https://www.nasdaq.com/market-activity/ ... t-interest

Yes, "topline results" in 2024. We already know the timeline.

What we NEED is some transparency about recruiting so we can see the odds of them meeting the timeline.

From the video: "There is no new data here"

Many cancer cures have been "found" (e.g. gene vectors to put in more copies of p53).

But only a REAL psychic can tell you when one will be APPROVED

Happy New Year, let's hope 2021 is less stupid than 2020.

> if you could look into my mind you would see something more akin to a lava lamp

Yes, that's the inevitable result of listening to four or more Calls Of Chipthulhu.

Best of luck to you karagozoglu12345 with your transplant process.

Be careful about catching anything while you're immune-suppressed, of course. Take your Vitamin D etc.

https://clinicaltrials.gov/ct2/show/NCT ... w=2&rank=2

Don't forget the recent large dilution at $1.30, and the fact that Scarlett is sitting on yet another ATM issue. If Geron had some good news (e.g., finally completing enrollment of a trial), Scarlett stands ready to crush the stock price yet again. The market has been burned by Geron dozens of times...

https://sci-hub.st/10.1080/17474086.2020.1831381

Paper stresses the need for a full-length Phase 3 on imetelstat, says that presently patients' main hope is stem cell transplant. Still, at least imet is on the radar.

There are at least four other drugs under consideration or awarded orphan status for myelofibrosis in the EU, including luspatercept: https://www.ema.europa.eu/en/search/search/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_orphan/field_ema_orp_disease_condition%253Aname_field/Tre...

I think it's clear cut... they haven't been able to recruit enough patients for the trials, and they're behind schedule. They're just making sure that they can cross the finish line on one trial before running out of money.

And it's not $75 million UNLESS they hit their milestones.

There was nothing "strange" about the volume on Friday, it was index rebalancing plus a little option expiration.

You've seen this a dozen times before, just look it up.

Yes, this is an important result. I posted about FortySeven last year, now they have GILD backing too. While they aren't starting out aiming at low risk MDS, this could limit Geron's expansion into AML... although it's always possible that the most effective genetic targets are different, or even th...

I'm sure Geron will get into ASH. Even if the trial results were negative, they're still human trial results on a new MOA, so are important either way.

@Ryan: not only did I not "knock" Geron's preclinicals... I DID the first preclinicals on imetelstat while I was at Shay-Wright lab :roll: And I lost a bundle when JNJ and Scarlett tricked us into believing that JNJ was going to continue (the "job posting", the compassionate-use listing, and all the...

Thanks for looking at the patents, HI. I agree that Geron's "concept patent" (something that is not supposed to exist) on "telomerase inhibitors in MF, MDS, and AML" (I know it's three blood cancers, hope I remember the AML correctly?) does apply. The other patents mention "modified Guanines" and in...

The patent on "any telomerase inhibitor in MF, MDS, and AML" should apply as well.

What they're discussing is waiving the pediatric testing requirement, as you'll remember was done for the Phase 2.

This is a very good thing, it will speed up the trial... and as biopearl points out, incidence in children is super rare.

Paper on MAIA's telomerase-inhibitor drug 6-thiodG coming out this month:

https://www.businesswire.com/news/home/ ... ncouraging